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Abstract
The pharmacokinetics of once-daily extended-release tacrolimus tablets (LCPT) in de novo liver transplantation have
not been previously reported. In this phase II, randomized, open-label study, de novo liver transplant recipients were randomized to LCPT 0.07–0.13 mg/kg/day (taken once daily; n = 29) or twice-daily immediate-release tacrolimus capsules
(IR-Tac) at 0.10–0.15 mg/kg/day (divided twice daily; n = 29). Subsequent doses of both drugs were adjusted to maintain tacrolimus trough concentrations of 5 to 20 ng/mL through day 90, and 5–15 ng/mL thereafter. Twenty-four-hour
pharmacokinetic profiles were obtained on days 1, 7, and 14, with trough concentration and efficacy/safety monitoring
through year 1. Similar proportions of patients in both groups achieved therapeutic trough concentrations on days 7
and 14 (day 7: LCPT = 78%, IR-Tac = 75%; day 14: LCPT = 86%, IR-Tac = 91%) as well as similar systemic and peak
exposure. There was a robust correlation between drug concentration at time 0 and area under the concentration-time
curve for both LCPT and IR-Tac (respectively, day 7: r = 0.86 and 0.79; day 14: r = 0.93 and 0.86; P < .0001 for all). Dose
adjustments during days 1 to 14 were frequent. Thirty-five patients completed the extended-use period. No significant
differences in adverse events were seen between groups. Incidence of biopsy-proven acute rejection (LCPT = 6 and
IR-Tac = 4) was similar on day 360. Between formulations, overall exposure was similar at 1 week after transplant with
the characteristic delayed-release pharmacokinetic profile of LCPT demonstrated in this novel population. These data
support further investigation of the safety and efficacy of LCPT in de novo liver transplantation.
Keywords
acute rejection, calcineurin inhibitor, immunosuppression, phase II, safety

Immediate-release, twice-daily tacrolimus (Prograf;
Astellas Pharma US, Inc., Northbrook, Illinois) was
approved by the US Food and Drug Administration in
1994 for prophylaxis of organ rejection in patients receiving liver transplants; since then, tacrolimus has become the cornerstone of immunosuppressive therapy
in liver transplantation. Currently, approximately 90%
of de novo and maintenance liver transplant recipients
are on an immunosuppression regimen that contains
tacrolimus.1
While tacrolimus is effective in preventing
rejection,2,3 the traditional formulation of immediaterelease twice-daily capsules (IR-Tac) exhibits some
challenging pharmacokinetic (PK) properties (eg, significant inter- and intraindividual variability in absorption and metabolism of tacrolimus).4,5 Tacrolimus has
poor bioavailability, poor water solubility, undergoes
extensive presystemic metabolism by cytochrome
P450 3A isoenzymes in the gut, and is a substrate
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for P-glycoprotein. The biliary route is the primary
elimination method for tacrolimus metabolites. As a
substrate for cytochrome P450 3A4 and cytochrome
P450 3A5, tacrolimus is subject to many drug-drug
interactions with other substrates, inhibitors, and
inducers.4 In addition, 2 doses per day are required;
more frequent daily dosing is associated with an
increased risk for poor adherence.6–9 Such noncompliance is discussed by Morrissey et al10 as a factor that
contributes to acute rejection and graft failure in renal
transplantation.
A novel formulation of extended-release tacrolimus
marketed as Envarsus XR (Veloxis Pharmaceuticals,
Inc., Cary, North Carolina) was approved by the US
Food and Drug Administration in December 2015.
This extended-release once-daily tablet (LCPT) increases the bioavailability of tacrolimus by the creation of a solid dispersion, or a solid solution, of the
drug substance through a physical process called “controlled agglomeration.” Prior randomized trials in renal transplant recipients comparing LCPT with IR-Tac
have shown that LCPT has greater bioavailability, a
steadier and more consistent concentration time profile over 24 hours, and reduced fluctuation (the peakto-trough change in drug concentrations around the average concentration)11 and swing (the peak-to-trough
change in drug concentrations relative to the minimum concentration)11 compared to IR-Tac.12 In addition, LCPT has demonstrated comparable efficacy,13
improved tolerability in regard to hand tremors,14 and
robust correlations between area under the concentration-time curve (AUC) and minimum whole blood
concentration (Cmin ) in trials evaluating the product in
renal transplantation.12,15–17
A single study has been published evaluating LCPT
in liver transplant recipients. In that phase II trial, stable liver transplant recipients who were converted from
IR-Tac to LCPT demonstrated consistent exposure, as
defined by AUC, at a lower total daily dose compared
to IR-Tac at steady state.18 Maximum whole blood
concentration (Cmax ), the Cmax /minimum concentration (Cmin ) ratio, and the percent of fluctuation and
swing were significantly lower with LCPT (P < .001),
while time to maximum concentration (tmax ) was significantly longer for LCPT vs IR-Tac (P < .001). AUC0–24
and Cmin correlation coefficients were ࣙ0.93 after 7 and
14 days of therapy following conversion. During the 52week trial extension period, none of the 49 patients in
the intent-to-treat population experienced graft loss or
death.18
The current phase II trial is the first to report the PK
of LCPT in a de novo liver transplant population randomized to LCPT tablets once daily or IR-Tac capsules
twice daily.
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Methods
Study Design
This phase II, open label, multicenter, randomized trial
(NCT00772148; Pharmacokinetics of LCP-TacroTM
R
Once Daily and Prograf 
Twice a Day in Adult De
Novo Liver Transplant Patients) was approved by the
following institutional review boards (IRBs): California
Pacific Medical Center IRB; Western IRB; Mayo Clinic
IRB; Biomedical Research Alliance of New York, LLC;
Piedmont Healthcare IRB; Stanford University Medical Center Administrative Panels Office; University
of California, San Francisco Committee on Human
Research, Office of Research; University of Cincinnati Medical Center IRB; University of Miami Human Subjects Research Office; University of Michigan
IRBMED; and the Washington University St. Louis
Human Research Protection Office. All subjects provided written informed consent before participating in
the study. The study was conducted according to the
International Conference on Harmonisation Guideline
for Good Clinical Practice and the United States Code
of Federal Regulations. The study was carried out at the
following sites: California Pacific Medical Center, LifeLink Healthcare Institute, Mayo Clinic Arizona, Mayo
Clinic Rochester, New York University, Piedmont Hospital, Stanford University Medical Center, University
of Alabama Birmingham, University of California San
Francisco, University of Cincinnati, University of Miami, University of Michigan, and Washington University in St. Louis.
Patient enrollment occurred between October 2008
and May 2010. Adult de novo liver transplant recipients were randomized to receive LCPT tablets once
daily or IR-Tac capsules twice daily, beginning within
72 hours of reperfusion. Patients swallowed all LCPT
tablets whole and without manipulation. Study centers
were permitted to follow their respective induction protocols; however, alemtuzumab use was not permitted.
Concomitant immunosuppressive therapy with mycophenolate mofetil, mycophenolic acid sodium, prednisone, or azathioprine was allowed; use of everolimus
or sirolimus was not permitted.
LCPT tablets were administered at a starting dose
of 0.07 to 0.11 mg/kg/day for all patients, except those
who self-identified as black (2 patients in each arm),
who received a starting dose of 0.09 to 0.13 mg/kg/day.
The differences in starting dose in this population was
a response to higher rates of tacrolimus metabolism
observed in blacks in previous clinical studies. Dose
selection within the dosing range was left to the clinician’s discretion. The initial total daily dose of IR-Tac
twice-daily capsules was 0.10 to 0.15 mg/kg/day for all
patients.19 All subsequent doses of both formulations
were investigator adjusted to achieve target whole blood

21607648, 2019, 8, Downloaded from https://accp1.onlinelibrary.wiley.com/doi/10.1002/cpdd.657 by Washington University School, Wiley Online Library on [03/11/2022]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

996

trough concentrations of 5 to 20 ng/mL until day 90,
and between 5 and 15 ng/mL thereafter, according to
standards of local practice. Dose adjustments to maintain tacrolimus whole blood trough levels within the
predefined therapeutic ranges were to be based on local laboratory determinations.
Pharmacokinetic Assessment. PK assessments following overnight fasts were performed on days 1 (24 hours
after drug initiation), 7, and 14. Blood samples for
LCPT or IR-Tac were collected 14 or 18 times per
day, respectively, per the following schedules: patients
on LCPT were tested before their morning LCPT dose
(0.0) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 14, 16, 20, and
24 hours after the single morning dose; patients on IRTac were monitored at the same time points with the
addition of tests at 12.5, 13, 13.5, and 15 hours after
the morning dose to better capture the second, midday
peak that occurs with this formulation.
All PK samples were analyzed in a central laboratory using high-performance liquid chromatography–
tandem mass spectrometry with an XTerra MS C8,
2.1 100 mm, 5-µm (Waters) column. Tacrolimus and
the internal standard, rapamycin, were extracted from
the whole blood sample using potassium ethylenediaminetetraacetic acid as an anticoagulant, by solid
phase extraction, into an organic medium, evaporated under nitrogen, and reconstituted in 200.0 µL
of mobile phase. The mobile phase was 90:10 v/v
methanol:0.002M ammonium acetate in 0.1% formic
acid. An aliquot of this extract was injected into a highperformance liquid chromatography system, detected
using a TSQ Quantum tandem mass spectrometer, and
quantitated using the peak area ratio method. Method
sensitivity and selectivity were achieved by detecting
distinct precursor-to-product ion mass transitions for
tacrolimus (821.5 → 768.5) and the internal standard,
rapamycin, (931.6 → 864.7) at a defined retention time
under reverse phase chromatographic conditions. The
procedure used to analyze tacrolimus is validated over
the range of 0.200 to 25.600 ± 10%. The within-day accuracy range was –2.9% to 0.5% and the between-day
accuracy range was –4.9 to 0.4% (percent coefficient of
variation).

Patients
Inclusion and Exclusion Criteria. Patients eligible for the
study were adult men and women ࣙ18 years of age who
were recipients of a liver transplant from a deceased
donor and had a Model for End-Stage Liver Disease
score of ࣘ30 at the time of transplantation.
The main exclusion criteria included receipt of a
liver from a non–heart-beating donor (ie, a donor
who was pronounced dead after cardiac death), receipt of any transplanted organ other than a liver,
or ABO incompatibility. Additionally, patients with
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gastrointestinal disorders or documented frank manipulation of the gastrointestinal tract that could have affected the absorption of tacrolimus were excluded. The
protocol did not specifically exclude patients with a history of Roux-en-Y hepaticojejunostomy.

Objectives
The primary objectives were to demonstrate the PK
of LCPT (AUC0-24h and Cmax ) and 24-hour trough
concentrations (C24 ) within the first 14 days after transplantation, and to compare the proportion of patients in each treatment group who achieved sufficient
tacrolimus whole blood trough concentrations within
the first 14 days after transplantation. Secondary objectives were to compare the PK of LCPT with the PK
of IR-Tac on study days 1, 7, and 14, and to evaluate
the efficacy and safety of LCPT compared to IR-Tac in
the first 12 months after liver transplantation.

Statistical Analysis
Analysis Populations. The analysis population included the modified intent-to-treat population (all randomized patients who received ࣙ1 dose of study
medication).

Statistical Methods
All demographic and baseline characteristics data, immunosuppression dosing data, laboratory data, and adverse events (AEs) were summarized using descriptive
statistics.
Pharmacokinetic Parameters. The tacrolimus concentration vs time profiles and PK parameters were calculated based on data from a central laboratory. PK
parameters were calculated using noncompartmental
analyses for tacrolimus as follows: AUC0-24h , Cmax ,
average plasma concentration (Cavg ), plasma concentration 24 hours after dosing (C24 ), tmax , percent fluctuation, percent swing, and accumulation ratio. PK
parameters and C24 were summarized using descriptive statistics on days 1, 7, and 14. Comparisons for the
PK parameters between treatments were performed using a 1-way analysis of variance model. The proportion
of patients in each study arm who achieved tacrolimus
whole blood trough concentrations within the recommended therapeutic range (5–20 ng/mL) was summarized on days 1, 7, and 14 based on the data from
local laboratories; the difference between the groups
was compared using Fisher’s exact test. Differences between the groups in total number of dose adjustments
during days 1 to 14 or during the course of study were
evaluated using a generalized linear model for Poisson
distribution based on likelihood ratio statistics and normalized to the extent of exposure (AUC0–24h ) during
each period of each subject.
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Figure 1. Subject disposition.

Efficacy and Safety
Patient and graft survival, and the cumulative incidence of biopsy-proven acute rejection (BPAR) (Banff
grade ࣙ1) at day 360 after transplantation were estimated using the product-limit (Kaplan-Meier) method
and compared between treatment groups using the
z-statistic. The severity of BPAR episodes was compared between treatment groups using a proportional
odds model. Liver function tests were conducted and
data collected throughout the study period. A measure
of renal function was based on the change from baseline for the estimated glomerular filtration rate (derived
using Equation 7 of the Modification of Diet in Renal Disease study). Baseline is defined as renal function
at day 42 after transplantation; this time point allows
for postoperative recovery and stabilization of renal
function. Renal function was then compared between
groups using a mixed-effects linear regression (random
intercept) model.
The proportion of LCPT and IR-Tac patients experiencing AEs was compared using Fisher’s exact test.
The primary goal of this study was to assess PK and
intended to be descriptive; based on LCPT phase I and
phase II study results, a sample size of 25 to 30 evaluable
patients was determined to be sufficient to characterize
the PK parameters of LCPT. A power analysis was not
conducted to determine the sample size needed to assess efficacy and safety outcomes; as such, the efficacy
and safety results should be interpreted considering this
limitation.

Results
Patients
A total of 58 de novo liver patients were randomized
and received at least 1 dose of a study drug (LCPT,
n = 29; IR-Tac, n = 29). The PK portion of the study

was completed by 76% of patients (LCPT, n = 21; IRTac, n = 23); patients completing the study through
day 360 numbered 17 (59% of the original 29) in the
LCPT group and 18 (62% of the original 29) in the IRTac group (Figure 1).
In the LCPT group, a total of 12 patients discontinued the study early; reasons documented were AEs
(4 patients), death (2 patients), and “other” (n = 6); in
the IR-Tac group, of the 11 early discontinuations, 2
were due to deaths, 1 to an AE, and 8 were attributed
to “other.”
Of the 58 patients enrolled in the study, 84.5% were
white. Overall, there were 40 (69%) men and 18 (31%)
women; the mean (standard deviation) age was 54.4
(8.55) years. The proportion of males in the LCPT
group (24; 82.8%) was higher than in the IR-Tac group
(16; 55.2%). For full demographic details, see Table 1.

Immunosuppression
Tacrolimus was initiated between 1 and 3 days after reperfusion; the median time to initiation was
2 days. Mean total daily doses are presented in
Table 2. A higher percentage of patients achieved therapeutic tacrolimus trough concentrations (5–20 ng/mL)
in the IR-Tac group (32.1%) on day 1 compared to
LCPT (13.8%). Mean locally analyzed trough concentrations over the first week are presented in Table 3.
On days 7 and 14, the proportions of patients achieving whole blood therapeutic tacrolimus trough concentrations were similar in both the LCPT and IR-Tac
groups (day 7, 78.3% vs 75.0%; day 14, 85.7% vs 91.3%,
respectively).
Dose adjustments were frequent; there was an average of 3.9 adjustments per LCPT patient and 4.8 per
IR-Tac patient in the first 14 days of treatment.
Concomitant immunosuppressive medications were
used by the modified intent-to-treat population; during
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Table 1. Demographic Characteristics—Modified Intent-toTreat Population

Characteristics

LCPT
(N = 29)a

IR-Tac
(N = 29)a

Overall
(N = 58)a

Sex, nb (%)
Male
24 (82.8)
16 (55.2)
40 (69.0)
Female
5 (17.2)
13 (44.8)
18 (31.0)
Age (y)
Mean (SD)
54.1 (7.27) 54.6 (9.78) 54.4 (8.55)
Median
55.0
55.0
55.0
Min-max
27–63
21–72
21–72
Race, nb (%)
American
0 (0.0)
1 (3.4)
1 (1.7)
Indian/Alaska native
Asian
1 (3.4)
2 (6.9)
3 (5.2)
Asian, native
1 (3.4)
0 (0.0)
1 (1.7)
Hawaiian/Pacific
Islander
Black/African
2 (6.9)
2 (6.9)
4 (6.9)
American
White
25 (86.2)
24 (82.8)
49 (84.5)
Ethnicity, nb (%)
Hispanic or Latino
5 (17.2)
2 (6.9)
7 (12.1)
Not Hispanic or
24 (82.8)
27 (93.1)
51 (87.9)
Latino
IR-Tac, twice-daily immediate-release tacrolimus capsules; LCPT, oncedaily extended-release tablet formulation of tacrolimus; SD, standard
deviation.
a Percentages based on the total number of patients in the modified
intent-to-treat analysis data set (N).
b n represents number of patients contributing to summary.
Source: Table 14.1.2.1, Listing 16.2.4.1.

days 1 to 14, a total of 48 patients received prednisone,
47 received CellCept (mycophenolate mofetil), and 57
received methylprednisolone. Concomitant antifungals
were more frequent in the LCPT vs IR-Tac group (fluconazole, LCPT 12 [41%] vs IR-Tac 8 [28%]; voriconazole, LCPT 2 [7%] vs IR-Tac 0).

systemic exposure (Cmax ) was approximately 55% lower
(P < .0001), and the concentration at the end of the
dosing interval (Cmin ) was approximately 30% lower for
LCPT (P = .057). However, a higher degree of fluctuation (P = .005) and swing (P = .020) followed the administration of IR-Tac vs LCPT. The median tmax of
LCPT was 12 hours, substantially longer compared to
2.67 hours for IR-Tac (P = .009).
On day 7, the overall systemic exposure of
tacrolimus was comparable following administration of LCPT vs IR-Tac. The Cmax was approximately
20% lower for LCPT vs IR-Tac, though this did not
reach statistical significance (P = .10). The Cmin was
comparable for both groups (P = .85). While the degree
of fluctuation was significantly higher for the IR-Tac
group compared to LCPT (P = .007), there were no
statistically significant differences in the degree of
swing (P = .08). The tmax of LCPT was significantly
longer (4 hours) compared to IR-Tac (1.51 hours)
(P = .03).
On day 14, following administration of LCPT vs
IR-Tac, the overall systemic exposure of LCPT was
approximately 11% higher (P = .38). The Cmax was
comparable for the 2 groups (P = .83), and the Cmin was
also comparable (P = .55). There were no statistically
significant differences in the degree of fluctuation (P =
.40) or swing (P = .83). Again, the median tmax of LCPT
was longer (4 hours) compared to IR-Tac (2 hours) (P =
.017). Normalization of the curves for AUC did not
alter the statistical significance of any PK parameters.
The correlation between dose-normalized AUC0–24h
and Cmin on day 1 was r = 0.53 for LCPT (P = .001)
and r = 0.74 for IR-Tac (P < .0001). By day 7, the
correlation between AUC0–24h and Cmin was high for
both LCPT (r = 0.86; P < .0001) and IR-Tac (r = 0.79;
P < .0001) (Figure 4). They remained highly correlated
at day 14 (LCPT: r = 0.93, P < .0001; IR-Tac: r = 0.86,
P < .0001) (Figure 5).

Pharmacokinetics
Table 2 provides a detailed description of PK findings of this study. Figure 2 shows the mean whole
blood tacrolimus concentrations on days 1, 7, and
14 for LCPT and IR-Tac. Table 4 and Figure 3 detail the exposure-normalized PK parameters of LCPT
vs IR-Tac and the exposure-normalized mean whole
blood concentration profiles, respectively. Exposure
normalization is an adjustment by which the AUC of
LCPT and IR-Tac are made equal, and all other PK
parameters mathematically adjusted, to allow direct
comparisons of PK parameters under assumption of
equivalent exposure.
Following the administration of LCPT on Day 1,
the overall systemic exposure (AUC0–24h ) of tacrolimus
was approximately 49% lower (P < .0001), the peak

Efficacy
The incidence of BPAR was similar in both groups; at
day 360, 6 (21%) patients on LCPT and 4 (14%) on
IR-Tac had experienced BPAR. The severity of the rejection events among patients treated with LCPT included: no Banff grade 3 events, 3 grade 2 events, and 3
grade 1 events. In comparison, of the 4 rejection events
in IR-Tac patients, 2 were grade 3 BPAR, and 2 were
grade 2 BPAR events. One additional patient in each
group was reported as having rejection without confirmatory biopsy. The Kaplan-Meier estimate of freedom
from BPAR at day 180 was 79% in the LCPT group and
87% (P = .61) in the IR-Tac group, and on day 360 was
74% in the LCPT group and 82% in the IR-Tac group
(P = .65).
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<.0001
.005
.02
.009

.057

<.0001

<.0001

9.78 ± 4.17
0.122 ± 0.059
231.94 (40.83)
251.29 ± 102.60
15.41 (46.04)
17.15 ± 7.90
6.67 (48.32)
7.33 ± 3.54
10.45 ± 4.25
92.70 ± 48.81
147.75 ± 96.90
4.00
(0.00–12.00)

8.29 ± 2.55
0.096 ± 0.017
116.17 (54.51)
135.62 ± 73.92
11.13 (49.48)
12.70 ± 6.29
3.62 (63.97)
4.42 ± 2.83
5.65 ± 3.08
159.89 ± 86.33
248.59 ± 183.80
2.67 (1.00–20.00)

9.33 ± 3.77
0.118 ± 0.054
226.87 (41.56)
245.47 ± 102.03
19.24 (42.52)
21.10 ± 8.97
6.83 (53.29)
7.61 ± 4.06
10.22 ± 4.24
134.22 ± 51.77
201.52 ± 105.38
1.51
(0.67–16.50)
.86
.007
.08
.03

.85

.10

.85

P-Valueb

6.48 ± 1.27
0.076 ± 0.014
59.57 (54.86)
68.18 ± 37.40
5.06 (58.15)
5.95 ± 3.46
2.55 (74.27)
3.22 ±2.39
2.84 ± 1.55
95.25 ± 80.45
137.92 ± 164.76
12.00
(1.48–24.20)

IR-Tac (n = 26)

LCPT (n = 23)

IR-Tac (n = 28)

LCPT (n = 29)
P-Valueb

Geometric Mean (%CV) Arithmetic Mean ± SD

Geometric Mean (%CV) Arithmetic Mean ± SD

9.43 ± 4.17
0.121 ± 0.064
254.24 (50.02)
279.59 ± 139.86
18.95 (46.64)
21.30 ± 9.93
6.68 (56.27)
7.41±4.17
11.66 ± 5.82
121.82 ± 62.34
204.95 ± 127.82
4.00
(1.00–16.00)

LCPT (n = 21)

9.65 ± 4.14
0.129 ± 0.070
229.55 (33.12)
241.22 ± 79.90
19.61 (63.47)
22.95 ± 14.57
7.17 (34.95)
7.56 ± 2.64
10.06 ± 3.33
140.49 ± 81.52
196.42 ± 131.51
2.00 (1.00–14.00)

IR-Tac (n = 23)

.37
.40
.83
.02

.55

.83

.38

P-Valueb

Geometric Mean (%CV) Arithmetic Mean ± SD

Day 14
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AUC0–24 , area under the concentration-time curve, 0 to 24 hours; Cavg , average concentration; Cmax , maximum concentration; Cmin , minimum concentration; CV, coefficient of variation; IR-Tac, twice-daily
immediate-release tacrolimus capsules; LCPT, once-daily extended-release tablet formulation of tacrolimus; PK, pharmacokinetics; SD, standard deviation; tmax , maximum time.
a Day 1 refers to level drawn 24 hours after drug initiation.
b P-value determined by analysis of variance.

Cavg (ng/mL)
Fluctuation (%)
Swing (%)
Tmax (hr) Median
(min-max)

Cmin (ng/mL)

Cmax (ng/mL)

Total daily dose (mg)
(mg/kg)
AUC0–24h (ng · h/mL)

PK Parameter

Day 7

Day 1a

Table 2. Summary of Tacrolimus PK Parameters—Modified Intent-to-Treat Analysis Set

1000

1001

Table 3. Locally Analyzed Tacrolimus Whole Blood Trough
(ng/mL) at Each Visit—PK mITT Population
LCPT
Arithmetic Mean (SD)

IR-Tac
Arithmetic Mean (SD)

5.02 (2.88)
22
6.83 (4.13)
26
6.57 (3.19)
28
8.90 (4.30)
25

5.86 (3.58)
23
7.42 (3.23)
25
7.80 (2.80)
26
9.59 (3.82)
25

Day 2a
(n)
Day 3a
(n)
Day 4a
(n)
Day 7a
(n)

IR-Tac, twice-daily immediate-release tacrolimus capsules; LCPT, oncedaily extended-release tablet formulation of tacrolimus; mITT, modified
intent-to-treat; PK, pharmacokinetics.
a Day refers to time after initiation of tacrolimus.

Safety
All patients experienced at least 1 AE during this openlabel study; serious AEs were reported in 58.6% of
LCPT patients (72% of which were suspected of being
related to the study drug by the investigator) and 34.5%
of IR-Tac patients (45% of which were suspected of
being related to the study drug by the investigator).
Although a larger number of patients experienced
serious AEs in the LCPT group, when comparing AE
percentages for both groups, the difference was not statistically significant (Table 5). The 6 most common AEs
reported in the entire study population were diarrhea
(41.4%), nausea (37.9%), headache (36.2%), peripheral
edema (36.2%), anemia (31.0%), and tremor (31.0%).
There were 2 deaths in each group during the study,
none of which were suspected to be study drug related.
The composite patient and graft survival rates out to
360 days after transplantation were 90.3% for LCPT
and 91.1% for IR-Tac (P = .952).
Liver function, as measured by aspartate transaminase, alanine transaminase, albumin, and total bilirubin
were similar between the 2 treatment groups throughout the course of the study with the exception of total
bilirubin on day 7, which was higher in the LCPT group
(Table 6).
The mean change from baseline in the estimated
glomerular filtration rate was not significantly different between the 2 groups (P = .78). There were no
statistically significant differences between the treatment groups for any of the predefined clinically significant laboratory parameters, including abnormalities
in fasting plasma glucose or hematologic parameters
(platelets, white blood cell counts).

Discussion
The characteristic peak exposure and larger degree of
fluctuation in exposure associated with IR-Tac were

evident during the PK portion of this study, while
LCPT showed a smaller degree of fluctuation and the
characteristically longer tmax . As a narrow therapeutic
index drug, a lower Cmax /Cmin ratio and less fluctuation
may represent more time within the target range; however, studies have not yet established the clinical significance of these PK parameters with tacrolimus. At
days 7 and 14, peak concentration and exposure were
comparable between LCPT and IR-Tac. Although a
lower proportion of patients on LCPT achieved therapeutic troughs on day 1, a similar proportion of patients in both groups met the therapeutic tacrolimus
trough targets at days 7 and 14. While bioavailability
was not specifically assessed in this PK study, doseadjusted AUC can be used as a surrogate for bioavailability. As demonstrated in other studies, the increased
bioavailability associated with LCPT allows for utilization of a lower dose to achieve similar systemic
exposure.12,13,15,16
On days 1, 7, and 14, tmax was significantly prolonged
with LCPT, which is consistent with a controlledrelease formulation. Additionally, there was a robust
correlation between AUC0–24h and Cmin with LCPT,
demonstrating that the current practice of therapeutic
drug monitoring of Cmin as a measure of tacrolimus
exposure can be applied to LCPT in liver transplant
patients. The day 1 PK of LCPT did not align with
day 7 and day 14 PK or with previously published
steady-state PK data in stable liver transplants.18 However, this is the first study to evaluate LCPT PK in the
immediate posttransplant period. In this study, day 1
(ie, 24 hours after the initiation of LCPT; median time
to drug initiation was 2 days) PK of LCPT exhibited
lower exposure, lower peak concentration, and lower
troughs compared with IR-Tac. Despite the improved
bioavailability of LCPT, it is possible that the recommended starting dose was too low. Furthermore, early
posttransplant PK are highly variable, and a patient’s
pretransplant health, transplanted liver, concomitant
medications, and postoperative care can all affect
the PK of administered drugs.20 Azoles were more
frequently used in the LCPT group than in the IR-Tac
group, although the concentration of tacrolimus would
be increased due to azoles’ inhibition of the hepatic
metabolism of tacrolimus.21 These variables may have
contributed to the low day 1 exposure. Considering
that LCPT has demonstrated higher bioavailability,
it is unclear why the variables would have disproportionately affected day 1 exposure of LCPT compared
with IR-Tac. Interestingly, lower day 1 exposure has
also been reported with once-daily extended-release
tacrolimus capsules (Tac-XL, Astagraf XL; Astellas
Pharma US, Inc., Northbrook, Illinois) compared
with IR-Tac, suggesting a possible challenge related
to absorption of extended-release formulations or
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Figure 2. 24-hour arithmetic mean whole blood tacrolimus concentrations (ng/mL) and SD on days 1, 7, and 14 for LCPT and IR-Tac.
All BLQ values entered as zero and included as such in the calculation of means. BLQ, below limit of quantification; IR-Tac, twice-daily
immediate-release tacrolimus capsules; LCPT, once-daily extended-release tablet formulation of tacrolimus; SD, standard deviation.
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IR-Tac
(n = 28)
8.29 ± 2.55
116.17 (54.51)
135.62 ± 73.92
11.13 (49.48)
12.7 ± 6.29
3.62 (63.97)
4.42 ± 2.83

LCPT
(n = 29)

12.64 ± 2.48
116.16 (54.86)
132.95 ± 72.94
9.86 (58.15)
11.6 ± 6.75
4.97 (74.27)
6.27± 4.66
.082

.44

.999

P-Valuec
9.64 ± 4.1
228.46 (40.83)
247.52 ± 101.01
15.18 (46.04)
16.89 ± 7.78
6.75 (48.32)
7.22 ± 3.49

LCPT
(n = 23)
9.33 ± 3.77
226.87 (41.56)
245.47 ± 102.03
19.24 (42.52)
21.10 ± 8.97
6.83 (53.29)
7.61 ± 4.06

IR-Tac
(n = 26)

.77

.083

.95

P-Valuec

Geometric Mean (%CV), Arithmetic Mean ± SD

Geometric Mean (%CV), Arithmetic Mean ± SD

8.44 ± 3.73
227.55 (50.02)
250.23 ± 125.17
16.96 (46.64)
19.06 ± 8.89
5.97 (56.27)
6.64 ± 3.73

LCPT
(n = 21)

9.65 ± 4.14
229.55 (33.12)
241.22 ± 79.90
19.61 (63.47)
22.95 ± 14.57
7.17 (34.95)
7.56 ± 2.64

IR-Tac
(n = 23)

.13

.38

.94

P-Valuec

Geometric Mean (%CV), Arithmetic Mean ± SD

Day 14 (Adjustment Factor 1 – 0.105)
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AUC0–24h , area under the concentration-time curve, 0 to 24 hours; Cmax , maximum concentration; Cmin , minimum concentration; CV, coefficient of variation; IR-Tac, twice-daily immediate-release tacrolimus
capsules; LCPT, once-daily extended-release tablet formulation of tacrolimus; mITT, modified intent-to-treat; PK, pharmacokinetics; SD, standard deviation.
a Exposure normalization is an adjustment by which the AUC of LCPT and IR-Tac are made equal, and all other PK parameters mathematically adjusted, to allow direct comparisons of PK parameters under
assumption of equivalent exposure.
b Day 1 refers to level drawn 24 hours after drug initiation.
c P-value determined by analysis of variance.

Cmin (ng/mL)

Cmax (ng/mL)

Total daily dose (mg)
AUC0–24h (ng · h/mL)

PK Parameter

Day 7 (Adjustment Factor 1 – 0.015)

Day 1ab (Adjustment Factor 1 + 0.95)

Table 4. Summary of Exposure Normalizeda Tacrolimus PK Parameters—mITT Analysis Set

DuBay et al
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Figure 3. 24-hour arithmetic mean whole blood tacrolimus concentrations (ng/mL) and SD on days 1, 7, and 14 for LCPT and
IR-Tac, exposure normalized.* All BLQ values entered as zero and included as such in the calculation of means. BLQ, below limit
of quantification; IR-Tac, twice-daily immediate-release tacrolimus capsules; LCPT, once-daily extended-release tablet formulation of
tacrolimus; SD, standard deviation.
*Exposure normalization is an adjustment by which the AUC of LCPT and IR-Tac are made equal, and all other pharmacokinetic
parameters mathematically adjusted, to allow direct comparisons of pharmacokinetic parameters under assumption of equivalent
exposure.
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Figure 4. Correlation between dose-normalized AUC0–24h and Cmin on day 7 for LCPT and IR-Tac. IR-Tac, twice-daily immediaterelease tacrolimus capsules; LCPT, once-daily extended-release tablet formulation of tacrolimus.

morning medication administration immediately after
transplantation.22
Dose adjustments were frequent in both groups.
As a result, the PK profiles observed do not reflect
steady-state kinetics, nor should they be assumed to
reflect a gradual approach to steady state. Based on
a tacrolimus half-life of approximately 36 hours and
assuming that 5 half-lives are required to approximate
steady-state conditions, a steady-state profile would
be expected following approximately 7 days of stable
LCPT or IR-Tac dosing. Those numbers would suggest
that steady state could be achieved with only 1 dose adjustment during the initial 14 days of PK monitoring.
But, in fact, all 58 patients randomized in the present
study had >1 dose adjustment, with an average of 4
and 5 for LCPT and IR-Tac, respectively, in the first
14 days of treatment. Future studies of LCPT in the

de novo setting are warranted to evaluate first-dose
kinetics and true steady-state kinetics far enough into
the treatment period to reflect consistent dosing. PK
of LCPT vs IR-Tac in stable liver transplant recipients
have been previously published.18 Conversion from
IR-Tac to LCPT in stable liver transplant recipients
showed that patients who were switched to LCPT at
a dose that was 30% less than their IR-Tac dose had
similar preconversion tacrolimus exposure (similar
AUC and troughs) 7 and 14 days after conversion.18
The primary outcome in the present study was PK;
however, efficacy and safety data were also captured.
The data suggest that LCPT and IR-Tac were associated with similar efficacy and safety in de novo liver
transplant use. Please note that the relatively small sample size for efficacy and safety outcomes and lack of a
power analysis preclude making definitive statements
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Figure 5. Correlation between dose-normalized AUC0–24h and Cmin on day 14 for LCPT and IR-Tac. IR-Tac, twice-daily immediaterelease tacrolimus capsules; LCPT, once-daily extended-release tablet formulation of tacrolimus.

regarding efficacy and safety. There were few BPAR
episodes in either group. Despite a higher number of
rejections in patients treated with LCPT (6 vs 4), patients treated with IR-Tac tended to experience more
severe rejection than those treated with LCPT. The incidence and types of AEs observed in this study were
representative of those typically seen in a de novo liver
transplant population being treated with a tacrolimusbased immunosuppressive regimen, and results did not
differ between the LCPT and IR-Tac groups.
This phase II PK study provides insight into
early posttransplant LCPT and IR-Tac PK; however,
interpretation of the results is complicated by variable
posttransplant PK conditions, lack of exclusion of interacting medications, and frequent dose adjustments.
Another limitation of the study is the small sample size
and lack of power analysis that limit the ability to draw
safety and efficacy conclusions.

Conclusions
This first analysis of LCPT PK in the de novo liver
transplant setting supports a conclusion that the novel
formulation allows for once-daily administration of
tacrolimus in de novo liver transplantation. Further
phase III study is warranted to confirm the similarity
between the drugs in efficacy and safety suggested here.
The PK results indicate that LCPT regimens may benefit from utilizing slightly higher starting doses than were
used in this de novo study.
Results of this 1-year study, in addition to those of
previous kidney de novo and conversion trials, a liver
conversion trial, and PK comparisons among LCPT,
IR-Tac, and Tac-XL support further investigation of
LCPT for de novo liver transplant patients.12,13,15–17,23
Future studies are warranted to examine whether oncedaily dosing and the unique PK parameters provided by
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ALT, alanine transaminase; AST, aspartate transaminase; IR-Tac, twice-daily immediate-release tacrolimus capsules; LCPT, once-daily extended-release tacrolimus tablets; mITT, modified intent-to-treat; SD,
standard deviation; Tbili, total bilirubin.
a Day 1 refers to level drawn 24 hours after drug initiation.
b P-value determined by analysis of variance.

IR-Tac
(n = 15)

45.8 ± 44.92
39.3 ± 30.17
0.79 ± 0.46
73.8 ± 109.58
79.1 ± 106.91
0.92 ± 0.72
.584
.916
.21
44.4 ± 78.54
78.2 ± 133.08
1.31 ± 0.70
33.6 ± 22.36
74.4 ± 56.72
1.50 ± 1.31
.373
.588
.019
54.6 ± 30.34
47.3 ± 24.37
161.5 ± 128.95 135.2 ± 91.14
3.66 ± 4.87
1.70 ± 1.04
.401
.127
.089
542.1 ± 586.89 386.2 ± 416.13
694.2 ± 873.08 434.1 ± 333.8
3.46 ± 4.08
2.52 ± 1.86
AST (U/L)
ALT (U/L)
Tbili (mg/dL)
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IR-Tac
(n = 22)

PValueb
Arithmetic Mean ± SD
Arithmetic Mean ± SD

Acknowledgments

IR-Tac
(n = 24)

Day 7
Day 1a

PValueb

LCPT are associated with safety or efficacy differences
in liver transplant recipients.

LCPT
(n = 26)

IR-Tac, twice-daily immediate-release tacrolimus capsules; LCPT, oncedaily extended-release tablet formulation of tacrolimus.

LCPT
(n = 26)

58 (100.0)
24 (41.4)
21 (36.2)
17 (29.3)
21 (36.2)
18 (31.0)
17 (29.3)
22 (37.9)
12 (20.7)
16 (27.6)
14 (24.1)
18 (31.0)
12 (20.7)
12 (20.7)
13 (22.4)
15 (25.9)

IR-Tac
(n = 29)

29 (100.0)
11 (37.9)
10 (34.5)
7 (24.1)
11 (37.9)
9 (31.0)
8 (27.6)
13 (44.8)
4 (13.8)
8 (27.6)
6 (20.7)
10 (34.5)
5 (17.2)
5 (17.2)
7 (24.1)
10 (34.5)

LCPT
(n = 29)

29 (100.0)
13 (44.8)
11 (37.9)
10 (34.5)
10 (34.5)
9 (31.0)
9 (31.0)
9 (31.0)
8 (27.6)
8 (27.6)
8 (27.6)
8 (27.6)
7 (24.1)
7 (24.1)
6 (20.7)
5 (17.2)

Liver
Function
Parameter

Any adverse events
Diarrhea
Edema, peripheral
Constipation
Headache
Anemia
Hepatitis C
Nausea
Hyperkalemia
Hypokalemia
Insomnia
Tremor
Fluid overload
Liver transplant rejection
Back pain
Hypomagnesemia

Arithmetic Mean ± SD

Overall
(N = 58)

Arithmetic Mean ± SD

IR-Tac
(N = 29)

Day 360

LCPT
(N = 29)

Day 14

Preferred Term

PValueb

Table 5. Adverse Events Experienced by ࣙ20% of Patients,
n (%)

.399
.189
.26
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